Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 25, 2025

5 Soft Drink Stocks to Hold Their Ground As Cost Pressures Mount

View original at finance.yahoo.com
5 Soft Drink Stocks to Hold Their Ground As Cost Pressures Mount The Zacks Beverages – Soft Drinks industry is facing mounting pressures as rising input costs and tariff uncertainty strain margins and complicate production planning…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • For the beverage business, PEP expects strong growth and market share gains from the liquid refreshment beverage category, with share gains in the carbonated soft drinks, RTD Tea and water categories

    80% confidence
  • Shifting consumer preferences toward healthier, natural and functional beverages are fueling innovation across plant-based drinks, botanical blends and wellness-focused formulations

    80% confidence
  • The top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1

    80% confidence
  • The company looks well-poised for growth, driven by its ability to drive brand volume growth via strong retail execution and creative marketing programs

    80% confidence
  • The Zacks Beverages - Soft Drinks industry currently carries a Zacks Industry Rank #147, which places it in the bottom 39% of more than 250 Zacks industries

    80% confidence
  • The Zacks Beverages - Soft Drinks industry is facing mounting pressures as rising input costs and tariff uncertainty strain margins and complicate production planning

    80% confidence
  • Management is optimistic about strength in the global energy drinks category

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
5 Soft Drink Stocks to Hold Their Ground As Cost Pressures Mount — Source | Via News | Via News